SCHYLER SMITH: Open Payments
NPI 1346972098 · ALBANY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$928 in 52 payments from 18 companies in 2025. Trend: 2023 $1,028 · 2024 $1,597 · 2025 $928
Food & beverage: $928
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $137 |
| ABBVIE INC. | 7 | $125 |
| AstraZeneca Pharmaceuticals LP | 4 | $89 |
| Sumitomo Pharma America, Inc. | 3 | $75 |
| Phathom Pharmaceuticals, Inc. | 6 | $66 |
| Lilly USA, LLC | 4 | $63 |
| GlaxoSmithKline, LLC. | 4 | $63 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
Products named: VRAYLAR, GEMTESA, Wegovy, VOQUEZNA, FARXIGA, MOUNJARO, JARDIANCE, XIFAXAN.
Industry payments across NY — which companies pay providers there.
